Autologous Whole Blood Injection For COVID-19 Can Reduce Cytokine Storm and Severity of Illness

Abstract

Autologous whole blood injection is used for various indications. It has an immunomodulatory actionon the immune system. A randomized controlled two-arm study was conducted to determine IL-6levels, CT changes and mortality among adult COVID-19 patients. The trial included 30 patientsdivided into two groups. The interventional group received 2 doses of 2.5 ml of autologous wholeblood injection spaced 2 days apart. There was a statistically significant reduction in IL-6 levels onday 6 in the group receiving treatment. CT score improved in patients who received treatment. Nocases of mortality were reported in the treatment group. Autologous whole blood injection can beused as a simple, low-cost adjuvant in the treatment of adult COVID-19 patients, regardless ofdisease severity.